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Objective: The purpose of this study is to clarify the significance of the 
particular involved organ as a prognostic factor and its relation to other 
previously reported factors. Methods: The prognoses of 194 consecutive 
patients with thymoma who had undergone complete or subtotal resec-
tion were reviewed retrospectively. Survival was evaluated as actuarial 
freedom from tumor death. Analysis of prognostic factors was per-
formed by the Kaplan-Meier method with the log rank test and Cox's 
proportional hazards model. Results: The Masaoka staging system and 
involvement of the great vessels were the independent prognostic factors 
in the entire study group; age, sex, histologic subtype, completeness of 
resection, association of myasthenia gravis, or involvement of other 
organs were not factors. The 10-year and 20-year survivals were 99% 
and 90% in stage I, 94% and 90% in stage II, 88% and 56% in stage III, 
30% and 15% in stage IVa, 0% and 0% in stage IVb, 93% and 83% in 
the absence of involvement of the great vessels, and 54% and 20% in the 
presence of it. Involvement of the great vessels was also the single inde-
pendent prognostic factor in the patients with stage III disease although 
completeness of resection or involvement of other organs were not. The 
10-year and 20-year survivals in patients with stage III disease were 
97% and 75% in the absence of involvement of the great vessels, and 
70% and 29% in the presence of it. Conclusion: Although the Masaoka 
staging system is a valuable prognostic factor, the category of stage III 
is heterogeneous and consists of 2 groups with distinct prognoses 
depending on involvement of the great vessels. (J Thorac Cardiovasc 
Surg 1999; 117 :605-13) 
Thymoma is a neoplasm arising from the epithelial cells of the thymus. I•2 Most thymomas are slow-
growing tumors, and tumor cells do not show a malig-
nant appearance despite their invasive nature. I ,2 
clinical staging system by Masaoka, which is based on 
the local extension of the tumor,15 has been shown to 
reflect the prognosis of thymoma, and the significance 
of this staging system as a prognostic factor has been 
confirmed by several other institutes.7•8,16,17 According 
to this staging system, however, cases that have involve-
ment of the pericardium, the lung, the great vessels, or 
other surrounding organs are all classified as stage III 
disease if pleural dissemination or distant metastases 
are not associated. Thus which organ is involved by the 
tumor is left out of consideration in this staging system. 
There have not been, however, any reports concerning 
the importance of the particular involved organ as a 
prognostic factor, except for several studies focusing on 
the reconstruction of the great veins in thymomal8,19 
and a study on thymic carcinoma.2o The significance of 
each involved organ as a prognostic factor and its rela-
tionship with other prognostic factors remain to be elu-
cidated. To clarify this issue, we analyzed the long-term 
results of surgical treatment for thymoma with special 
The main therapeutic strategy in the treatment of thy-
moma is surgical resection,3-s and the outcome of sur-
gical treatment for this disease has been shown to 
depend on the local invasiveness of the tumor.9-14 The 
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Table I. Association of myasthenia gravis, completeness of resection, and involved organs according to the 
Masaoka staging system in patients with thymoma 
Myasthenia gravis Resection Involved organ 
Stage (+) (-) Complete Subtotal Pleura Pericardium Lung Great vessels 
I 78 45 33 78 0 0 0 0 0 
II 44 33 11 44 0 31 0 0 0 
III 56 27 29 50 6 52 30 41 20 
IVa 10 4 6 0 10 10 8 8 6 
IVb 6 0 6 0 6 6 5 6 4 
Total 194 109 85 172 22 99 43 55 30 
Table II. Survival of patients according to the Masaoka staging system 
Stage 
II 
III 
IVa 
IVb 
'Mean ± SE. 
JOy 
99 (96-101) 
94 (87-102) 
88 (78-97) 
30 (2-58) 
o 
Survival (95% Cl) 
20y 
90 (78-102) 
90 (79-101) 
56 (36-77) 
15 (-10-40) 
reference to the involved organs with other previously 
reported prognostic factors, based on the retrospective 
review of 194 consecutive patients who underwent sur-
gical treatment at our institute. 
Patients and methods 
Patients. Thymoma is defined as a tumor that originates 
from the thymic epithelial cells but does not show an appar-
ent malignant morphologic condition.1,2 The epithelial 
tumors that are obviously malignant cytologically were 
referred to as thymic carcinomas in this study, according to 
classification of thymic epithelial tumors by Snoover and 
associates21 and Suster and Rosai. 22 Therefore malignant 
lymphomas, germ cell tumors, carcinoids, thymic carcino-
mas, and thymic hyperplasia were excluded in this study. 
The extent of the tumor was evaluated before the operation 
by routine chest radiographic examination, conventional 
chest computed tomography, and recently by magnetic reso-
nance imaging. A total of 208 patients with thymoma were 
treated at Osaka University Hospital from January 1957 to 
June 1996. Four patients who had received their initial surgi-
cal treatment at other institutes and another 10 patients who 
underwent a biopsy only were excluded from this study. 
Accordingly, the study group consisted of 194 patients who 
underwent complete or subtotal resection at our institute. 
There were 107 male and 87 female patients. The age of the 
patients ranged from 10 to 74 years, and the median age was 
45 years (mean ± standard deviation: 45.5 ± 13.0 years). 
Myasthenia gravis was associated in 109 patients (56.2%). 
Years 
35.67 ± 1.35 
28.05 ± 1.20 
21.71 ± 1.51 
8.89 ± 2.47 
2.28 ± 0.61 
Mean survival time' 
95%CI 
33.03-38.31 
25.69-30.40 
18.76-24.67 
4.04-13.74 
1.08-3.48 
Other associated diseases were pure red cell aplasia (7 
patients), rheumatoid arthritis (2 patients), systemic lupus 
erythematosus (1 patient), Graves' disease (I patient), 
Hashimoto's disease (1 patient), Sjogren syndrome (1 
patient), and pemphigus vulgaris (1 patient). 
The thymomas were classified histologically on the basis 
of the predominance of epithelial cells or lymphocytes 
according to the proposal of Bernatz and associates,23 and 53, 
38, and 102 thymomas were classified into the predominantly 
lymphocytic type, the predominantly epithelial type, and the 
mixed lymphoepithelial type, respectively. The histologic 
subtype in 1 patient with stage III disease was not determined 
because of extensive necrosis induced by preoperative 
chemotherapy. 
The involved organs in each patient were confirmed by 
critical review of the records of operation. The great vessels 
refer to the brachiocephalic veins, the superior vena cava, or 
the aorta in this study. 
Association of myasthenia gravis, completeness of resec-
tion, and the involved organs according to the Masaoka stag-
ing system are presented in Table 1. In the patients with stage 
IV disease, resection was judged as subtotal even when all the 
lesions appeared to be removed. 
As a postoperative adjuvant therapy, radiation to the medi-
astinum was administered to all patients until 1985; since 
1986, radiation to the mediastinum has been limited to those 
patients with invasive thymoma, including stage II, III, and 
IV diseases. Chemotherapy was generally performed in 
patients with stage IV disease. Patients with stage III disease 
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whose surgical treatment was incomplete resection also 
received adjuvant chemotherapy. 
The outcome of patients was confirmed by the physicians' 
records and direct contact with patients by telephone. 
Postoperative follow-up study was performed by annual chest 
radiographic examination; when tumor recurrence was sus-
pected, chest computed tomography was added. In recent 
cases, magnetic resonance imaging was also used for further 
evaluation. Seven patients in the study group required a sec-
ond surgical treatment for recurrent tumors afterward. The 
follow-up period ranged from 2 months (death from myas-
thenia gravis) to 38 years, and the median follow-up period 
was 10.3 years (mean ± SD; 11.3 ± 7.8 years). Sixty-six 
patients died during the follow-up period. Although 32 
patients died of a tumor, 34 patients died of accidents or other 
diseases including crisis of myasthenia gravis (12 patients). 
One hundred patients, including 4 with tumor recurrence, 
were alive in January 1998. Nineteen patients were alive at 
some point between 1991 and 1997. The remaining 9 patients 
were lost to follow-up before 1991 at 23, 23, 15, 13, 10,8,7, 
and 7 years, and 3 months after operation, respectively. 
Statistical analysis. To focus on the oncologic behavior of 
thymoma, the patients who died of other diseases or accidents 
were dealt with as drop-out cases at the time of the event. In 
this study therefore survival refers to freedom from tumor 
death. The actuarial survivals were calculated with the 
method of Kaplan and Meier. The statistical difference of sur-
vival was examined with the log rank test. The relative impor-
tance of various prognostic factors for postoperative survival 
as identified by multi variable analysis was analyzed with 
Cox's proportional hazards model with the forward stepwise 
method. Association between categoric variables was exam-
ined by the X2 test or Fisher's exact test. The statistical dif-
ference of the mean value was examined by the Student t test. 
Statistical analyses were performed with the commercially 
available personal computer program SPSS (SPSS, Inc, 
Chicago, Ill). 
Results 
Factors associated with survival of all patients. 
The survival curves according to the Masaoka staging 
system are shown in Fig 1. The 10- and 20-year sur-
vivals and the mean survival times are also presented in 
Table II. There was a significant difference in survival 
between stage I and stage III (P = .002), between stage 
I and stage IVa (P < .0001), between stage I and stage 
IVb (P < .0001), between stage II and stage IVa (P < 
.0001), between stage II and stage IVb (P < .0001), 
between stage III and stage IVa (P < .0001), between 
stage III and stage IVb (P < .0001), and between stage 
IVa and stage IVb (P = .04). There was a marginal dif-
ference between stage II and stage III (P = .06). 
Next, we examined the significance of other prognos-
tic factors such as age, sex, histologic subtype, com-
pleteness of resection, involvement of the surrounding 
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Fig 1. Survival according to the Masaoka staging system. The 
patients who died of other diseases or accidents were dealt 
with as drop-out cases at the time of the event; thus survival 
refers to actuarial freedom from tumor death. The number of 
patients at risk at 10, 20, and 30 years after operation is pre-
sented under the curves. 
organs, and association of myasthenia gravis, by uni-
variate analysis. There was a significant difference in 
survival according to completeness of resection (P < 
.0001), involvement of the pleura (P < .0001), involve-
ment of the pericardium (P < .0001), involvement of the 
lung (P < .0001), or involvement of the great vessels (P 
< .0001). Table III shows 10- and 20-year survivals and 
mean survival times according to these factors. The sur-
vival curves according to completeness of resection and 
involvement of the great vessels are shown in Figs 2 and 
3, respectively. On the other hand, there was no signifi-
cant difference in survival according to age «45 years 
vs >45 years; P = .50), sex (P = .42), or histologic sub-
type (P = .55). There was a marginal difference in sur-
vival between the patients with myasthenia gravis and 
those without it (P = .07). 
By multivariate analysis with Cox's proportional 
hazards model, Masaoka's clinical stage and the 
involvement of the great vessels were shown to be the 
independent factors to determine postoperative sur-
vival. The P value, the relative risk, and 95% confi-
dence interval (CI) of each factor are presented in 
Table IV. Survival did not, however, depend on age (P 
= .31), sex (P = .45), histologic SUbtype (P = .74), 
association of myasthenia gravis (P = .32), complete-
ness of resection (P = .16), involvement of pleura (P = 
.96), involvement of the pericardium (P = .48), or 
involvement of the lung (P = .46) according to the 
multivariate analysis, although the univariate analyses 
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Fig 2. Survival according to completeness of resection. 
Survival refers to actuarial freedom from tumor death. The 
numbers in parentheses below each curve denote the number 
of patients at risk at a given time point after operation. 
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Fig 3. Survival according to the presence or absence of 
involvement of the great vessels (GV). Survival refers to actu-
arial freedom from tumor death. The numbers in parentheses 
below each curve denote the number of patients at risk at a 
given time point after operation. 
Table III. Survival of patients according to completeness of resection, involved organ, and association of 
myasthenia gravis 
Survival (95% CI) 
Factor lay 20y 
Resection 
Complete 94 (90-98) 82 (73-91) 
Subtotal 38 (17-59) 10 (-7-26) 
Great vessels 
Not involved 93 (89-98) 83 (74-92) 
Involved 54 (34-73) 20 (-1-41) 
Pleura 
Not involved 98 (94-101) 91 (81-100) 
Involved 77 (68-86) 54 (38-69) 
Pericardium 
Not involved 94 (89-98) 80 (70-90) 
Involved 65 (49-81) 42 (21-63) 
Lung 
Not involved 95 (91-99) 86 (78-95) 
Involved 69 (56-82) 43 (25-61) 
Myasthenia gravis 
Not Associated 82 (73-90) 69 (55-83) 
Associated 91 (85-97) 73 (60-87) 
'Mean ± SE. 
Table IV. Independent prognostic factors according to 
Cox's proportional hazards model 
Factor Relative risk 95% Cl P value 
Involvement of the 2.4862 1.1621-5.3189 .02 
great vessels 
Masaoka stage 3.4399 2.1891-5.4055 <.0001 
showed that the latter 4 factors were related with sur-
vival (Table III). 
Factors associated with survival of patients with 
stage III disease. The significance of the prognostic 
Mean survival time 
, 
Years 95%Cl P value 
33.48 ± 1.12 31.28-35.68 
9.11 ± 1.67 5.83-12.39 <.0001 
33.42 ± 1.14 31.17-35.66 
12.19±1.74 8.78-15.59 <.0001 
35.66 ± 1.18 33.34-37.98 
20.96 ± 1.40 18.21-23.71 <.0001 
32.89 ± 1.26 30.42-35.35 
15.15 ± 1.52 12.18-18.13 <.0001 
34.32 ± 1.15 32.08-36.57 
17.73 ± 1.65 14.50-20.95 <.0001 
28.62 ± 1.96 24.78-32.45 
28.06 ± 1.31 25.49-30.63 .07 
factors examined earlier were also assessed by both 
univariate and multivariate analyses in patients with 
stage III disease. 
Table V denotes 10- and 20-year survivals and the 
mean survival time of patients with stage III disease, 
according to the prognostic factors examined. By uni-
variate analysis, there was a significant difference in 
the survival of patients with stage III disease accord-
ing to completeness of resection and involvement of 
the great vessels. There was no statistical difference, 
however, in survival of patients with stage III disease 
according to involvement of the pleura, the pericardi-
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Table V. Survival of patients with stage III disease according to completeness of resection, involved organ, and 
association of myasthenia gravis 
Survival (95% el) 
Factor JOy 20y 
Resection 
Complete 88 (79-98) 68 (49-87) 
Subtotal 83 (54-113) 0 
Great vessels 
Not involved 97 (91-103) 75 (52-98) 
Involved 70 (48-92) 29 (0-59) 
Pleura 
Not involved 100 100 
Involved 86 (76-97) 54 (32-75) 
Pericardium 
Not involved 91 (79-103) 59 (32-86) 
Involved 85 (70-99) 57 (29-85) 
Lung 
Not involved 93 (79-106) 70 (29-110) 
Involved 86 (74-97) 54 (31-76) 
Myasthenia gravis 
Not associated 83 (68-98) 70 (48-91) 
Associated 92 (80-102) 44 (11-76) 
ND, Not calculated, because all !be patients were alive at the last follow-up. 
*Mean ± SE. 
um, or the lung or association of myasthenia gravis, 
unlike the results obtained by univariate analyses 
from all patients (Table III). The survival curves of 
patients with stage III disease according to presence 
or absence of involvement of the great vessels are 
shown in Fig 4. 
Multivariate analysis was again adopted to determine 
the independent prognostic factors in patients with stage 
III disease. Similarly to the results obtained in the entire 
study group (Table IV), involvement of the great vessels 
was the only independent factor to determine postoper-
ative survival with the relative risk of 4.936 (95% el, 
1.517 to 16.061; P = .008), although association of 
myasthenia gravis (P = .42), completeness of resection 
(P = .69), involvement of the pleura (P = .16), involve-
ment of the pericardium (P = .99), or involvement of the 
lung (P = .47) were not independent factors. 
Table VI denotes the relation of involvement of the 
great vessels to other factors. Although there was no 
significant relation between involvement of the great 
vessels and of each age, sex, association of myasthenia 
gravis, histologic SUbtype, or involvement of other 
organs, there was a significant relation between the 
involvement of the great vessels and completeness of 
resection (P = .001). 
Finally, we examined the relation between involve-
ment of the great vessels and tumor recurrence. 
Fourteen of 20 patients with stage III disease with 
involvement of the great vessels underwent complete 
Mean survival time * 
Years 95%CI P value 
23.21 ± 1.52 20.25-26.17 
14.68 ± 2.06 10.64-18.71 .04 
25.03 ± 1.52 22.05-28.02 
15.36 ± 2.05 11.34-19.39 .003 
NO ND 
21.28 ± 1.58 18.18-24.37 .31 
22.56 ± 1.96 18.72-26.40 
18.59 ± 1.62 15.42-21.75 .52 
20.92 ± 2.45 16.11-25.72 
21.26 ± 1.71 17.91-24.60 .59 
22.51 ± 2.08 18.43-26.59 
20.50 ± 1.88 16.81-24.19 .85 
resection. Seven (50%) of these 14 patients experi-
enced tumor recurrence, and distant metastases to the 
lung, the liver, or the kidney were found in 5 patients. 
All 36 patients with stage III disease with no involve-
ment of the great vessels were treated by complete 
resection; tumor recurrence was experienced by only 6 
of these patients (17%). 
Discussion 
Prognostic factors determining the outcome of surgi-
cal treatment for thymoma have been extensively dis-
cussed but are still controversiap,8,16,17,24 This seems 
partly because thymoma is an uncommon and slow-
growing tumor. This forces the investigators studying 
the prognostic factors to observe the patients for a much 
longer follow-up period compared with other malignant 
diseases, and this condition inevitably brings about the 
high incidence of patient death from other diseases dur-
ing the follow-up period. Additionally, associated 
autoimmune diseases such as myasthenia gravis and 
pure red cell aplasia are sometimes life-threatening. For 
this reason, as many as 34 of 66 postoperative deaths 
(52%) were not related to the tumor's progress in our 
series. Therefore the analytic method used in this study 
and other reports,6,17 in which patients who died of the 
other diseases or accidents were dealt with as the drop-
out cases, is supposed to be justified when focusing on 
the oncologic behavior of thymoma. 
Another important issue in the research of thymomas 
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Table VI. Relation between involvement of the great vessels and other factors 
Great vessels not involved (36 patients) 
Factor No. Proportion 95%CI 
Age (y) 44.5 ± 11.4' 40.8-48.2 
Sex 
Male 22 61 45-77 
Female 14 39 23-55 
Myasthenia gravis 
Associated 16 44 28-60 
Not associated 20 56 40-72 
Histologic condition 
Epithelial 9 26 11-41 
Mixed 20 57 40-74 
Lymphocytic 6 17 4-30 
Pleura 
Not involved 2 6 -2-14 
Involved 34 94 86-102 
Pericardium 
Not involved 19 53 36-70 
Involved 17 47 30-64 
Lung 
Not involved 10 28 13-43 
Involved 26 72 57-87 
Resection 
Complete 36 100 100-100 
Subtotal 0 0 0-0 
'Mean ± SD. 
is the confusion between thymoma and thymic carcino-
ma. Levine and Rosai2 first classified invasive thymo-
mas into 2 categories: category I malignant thymoma, 
which have no or minimal cytologic atypia, and cate-
gory II malignant thymoma, which are obviously 
malignant cytologically. Category II malignant thymo-
ma was later defined as thymic carcinoma by this 
group.2.21,22 More recently, Miiller-Hermelink and 
associates25,26 proposed a new classification of thymo-
ma based on the origin of the neoplastic epithelial cell, 
that is, the cortical type or the medullary type. This 
group later added another category and named well-dif-
ferentiated thymic carcinoma.27 Thymic tumors of this 
category are characterized by a predominance of 
epithelial cells, an epidermoid differentiation with 
slight to moderate cytologic atypia, the constant pres-. 
ence of interepithelial immature cortical thymocytes, 
lobular growth, and formation of epithelial palisades 
around perivascular spaces. On the other hand, the most 
recent classification of thymic epithelial tumors pro-
posed by Shimosato and Mukai28 takes into considera-
tion whether the neoplastic epithelial cells still hold the 
thymic epithelial function to induce immature T cells 
from bone marrow-derived T-cell precursors; the 
tumors that retain this function are defined as thymoma 
Great vessels involved (20 patients) 
No. Proportion 95%CI P value 
46.9 ± 12.2' 41.5-52.3 .48 
10 50 28-72 
10 50 28-72 .60 
11 55 33-77 
9 45 23-67 .63 
4 20 2-38 .75 
11 55 33-77 
5 25 5-45 
2 10 -4-24 
18 90 76-104 .61 
7 35 14-56 
13 65 44-86 .32 
5 25 5-45 
15 75 55-95 1.00 
14 70 49-91 
6 30 9-51 .001 
although thymic carcinomas do not hold it any more. 
The fact that Miiller-Hermelink and associates' well-
differentiated thymic carcinoma contains immature 
cortical thymocytes suggests that this tumor still holds 
the thymic epithelial function. In this sense, Shimosato 
and Mukai included Miiller-Hermelink and associates' 
well-differentiated thymic carcinoma in a group of 
atypical thymomas. The high incidence of association 
with myasthenia gravis in these tumors also suggests 
the biologic analogy to benign thymomas. In this study, 
thymic carcinomas were defined according to the defi-
nition of Rosai and associates21 ,22 and were excluded 
from the study group. On the other hand, Miiller-
Hermelink and associates' well-differentiated thymic 
carcinoma were included in the study group, following 
Shimosato and Mukai's definition. 
Under these conditions, the univariate analyses in 
this study demonstrated that the Masaoka staging sys-
tem and completeness of resection are significant prog-
nostic factors, consistent with previous reports.5-8,14-17 
According to the Masaoka staging system, the progno-
sis of patients with stage I and II diseases was extreme-
ly good with a 30-year survival of 90% (Fig I). On the 
contrary, the survival of patients with stage III, IVa, or 
IVb disease deteriorates as the stage progresses. The 
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multivariate analysis also revealed that the Masaoka 
staging system is a significant factor. Thus the 
Masaoka staging system is demonstrated to be highly 
valuable as a prognostic factor of thymoma when sur-
vival was evaluated in terms of freedom from tumor 
death. Although completeness of resection was also 
shown to be a significant prognostic factor by univari-
ate analysis (Fig 2), as reported by other investiga-
tors,6.16 it no longer appeared as an independent factor 
by multivariate analysis. In place of it, involvement of 
the great vessels was chosen as an independent prog-
nostic factor along with Masaoka staging system 
(Table IV). Furthermore, although univariate analyses 
showed that survival depends on involvement of each 
surrounding organ such as the pleura, the pericardium, 
the lungs, or the great vessels (Table III), none of these 
factors were considered as an independent prognostic 
factor by multivariate analysis. These results are pre-
sumed to come from the situation in which the 
Masaoka staging system or involvement of the great 
vessels are related to each of the remaining factors. 
Association of myasthenia gravis was also reported to 
be one of the prognostic factors. This was derived from 
perioperative deaths from myasthenia gravis in the ear-
lier days.29 However, association of myasthenia gravis 
is no longer considered an adverse factor in survivaI,24 
Conversely, Maggi and associates7 reported that associ-
ation of myasthenia gravis contributes to early discov-
ery of associated thymoma, thus allowing a better sur-
vival for patients with thymoma associated with 
myasthenia gravis compared with those not associated 
with it. Because our institute is one of the centers for 
surgical treatment of myasthenia gravis in Japan, this 
seems to result in the high incidence of association with 
myasthenia gravis in this series and is presumed to have 
presented the result similar to Maggi and associates. By 
multivariate analysis, however, association of myasthe-
nia gravis was no longer an independent prognostic fac-
tor. This might come from the higher proportion of 
patients with earlier stages when associated with myas-
thenia gravis. Actually, in this series, the proportion of 
patients with stage I or II disease was 71.6% in cases 
associated with myasthenia gravis and 51.7% in cases 
not associated with it (Table I). 
Because the category of stage III according to the 
Masaoka staging system seems to be highly heteroge-
neous in terms of the involved organs and the com-
pleteness of resection, as pointed out by Rea and asso-
ciates,30 univariate and multivariate analyses were 
again performed according to those prognostic factors 
in patients with stage III disease. Although both com-
pleteness of resection and involvement of the great ves-
100 
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Fig 4. Survival of patients with stage III disease according to 
the presence or absence of involvement of the great vessels 
(GV). Survival refers to actuarial freedom from tumor death. 
The numbers in parentheses below each curve denote the 
number of patients at risk at a given time point after operation. 
sels were considered to be the prognostic factors by 
univariate analysis, the multivariate analysis demon-
strated that involvement of the great vessels is the sin-
gle independent prognostic factor. The significant rela-
tion between completeness of resection and 
involvement of the great vessels shown in Table VI 
explains that these 2 factors are well linked. Actually, 6 
of 20 patients with involvement of the great vessels 
underwent subtotal resection. Even in the remaining 14 
patients who underwent complete resection, tumor 
recurrence occurred in 7 patients (50%), and the 
relapsed sites included distant organs in 5 patients. 
Thus involvement of the great vessels seems to have a 
greater adverse effect on survival than completeness of 
resection. Postoperative radiation with or without 
chemotherapy was the main strategy for adjuvant ther-
apy to those patients with involvement of the great ves-
sels in our series. Rea and associates30 and Macchiarini 
and associates3l attempted a prospective, single-arm 
treatment study investigating induction chemotherapy 
with surgical intervention. Considering the effective-
ness in reduction of tumor by induction chemotherapy, 
this approach seems to be recommended for cases of 
highly invasive stage III thymoma, especially with 
involvement of the great vessels. 
Blumberg and associates20 reported the prognosis of 
thymic carcinomas and determined that involvement of 
the great vessels is an independent prognostic factor. 
This was quite similar to our result. On the other hand, 
the Masaoka staging system had no impact on survival 
in the series of Blumberg and associates. The inconsis-
tency between the results from our series and Blumberg 
and associates might be derived from the difference 
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between our patient group and Blumberg and associ-
ates patient group, which is composed mostly of thy-
mic carcinomas as described by Rosai and associ-
ates.21 ,22 The difference of clinical implication of the 
Masaoka staging system between these 2 studies might 
reflect the oncologic distinction between thymomas 
and thymic carcinomas. 
In conclusion, the Masaoka staging system and 
involvement of the great vessels were independent prog-
nostic factors in our series of thymomas. Involvement of 
the great vessels was also an independent prognostic 
factor in patients with stage III disease. Thus the cate-
gory of stage III disease in the Masaoka staging system 
is a heterogeneous group, consisting of 2 subgroups 
with distinct prognosis depending on involvement of the 
great vessels. Involvement of the great vessels was sug-
gested to be an essential factor in determining the ther-
apeutic modality for stage III thymoma. 
We thank Dr Toshiro Nishida for help in statistical analysis. 
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Commentary 
The article by Okumura and associates should be 
compared with that of Blumberg and colleagues I with 
regard to the prognostic significance of thymic tumors 
involving the great vessels. Both articles seem to yield 
the same results, despite the fact that in the current pub-
